Literature DB >> 8422670

Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene.

L Ding1, E N Lalani, M Reddish, R Koganty, T Wong, J Samuel, M B Yacyshyn, A Meikle, P Y Fung, J Taylor-Papadimitriou.   

Abstract

The immune response of CAF1 mice to various synthetic peptides (SP) related to the amino acid sequence (PDTRPAPGSTAPPAHGVTSA) of the tandem repeat of the MUC1 human breast mucin core peptide was evaluated. The most immunogenic preparations of the synthetic peptides were those conjugated to keyhole limpet hemocyanin (KLH) or clustered in a dendritic multiple antigenic peptide (MAP-4) configuration. The mice were immunized subcutaneously with synthetic peptides emulsified in RIBI adjuvant, employing various immunization protocols. Equivalently high IgG responses were induced using SP-KLH conjugates (GVTSAPDTRPAPGSTA-KLH) or an SP--MAP-4 chimeric configuration (SP1-6), which also included a universal malarial CST-3 T-helper epitope (SP1-6 = SAPDTRPAEKKIAKMEKASSVFNVVNS--MAP-4). These IgG antibodies bound both the appropriate MUC1 synthetic peptides and the cell surface expressed MUC1 mucin on murine mammary cells that had been transfected with the human MUC1 gene and a human breast cancer cell line that expresses cell-surface MUC1. A MAP-4 molecule, which included the entire 20-amino-acid sequence of the MUC1 tandem repeat (SP1-5 = PDTRPAPGSTAPPAHGVTSA-MAP-4) induced a poor IgG response. In contrast, all three types of molecule: SP-KLH, SP1-6 and SP1-5, were found to be good immunogens for the induction of specific delayed-type hypersensitivity (DTH) reactions measured using either synthetic peptides or MUC1-transfected cells. In addition, immunization with irradiated MUC1-transfected cells induced strong DTH reactions measured using synthetic peptides that expressed the PDTRP sequence, which has been shown to be, or to overlap, a T cell epitope in humans and a B cell epitope in mice. Finally, it was demonstrated that synthetic MUC1 peptide "vaccines" could be used both prophylactically and therapeutically to inhibit the growth of MUC1-transfected tumor cells and prolong the survival of tumor-bearing mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8422670     DOI: 10.1007/bf01789125

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  32 in total

1.  T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivo.

Authors:  C M Henningsson; S Selvaraj; G D MacLean; M R Suresh; A A Noujaim; B M Longenecker
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 2.  Cell-surface macromolecular and morphological changes related to allotransplantability in the TA3 tumor.

Authors:  J F Codington; D M Frim
Journal:  Biomembranes       Date:  1983

3.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.

Authors:  D L Barnd; M S Lan; R S Metzgar; O J Finn
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Signal transduction via leukocyte antigen CD43 (sialophorin). Feedback regulation by protein kinase C.

Authors:  R C Wong; E Remold-O'Donnell; D Vercelli; J Sancho; C Terhorst; F Rosen; R Geha; T Chatila
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

5.  CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen.

Authors:  M Kahn; H Sugawara; P McGowan; K Okuno; S Nagoya; K E Hellström; I Hellström; P Greenberg
Journal:  J Immunol       Date:  1991-05-01       Impact factor: 5.422

6.  Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.

Authors:  K R Jerome; D L Barnd; K M Bendt; C M Boyer; J Taylor-Papadimitriou; I F McKenzie; R C Bast; O J Finn
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

7.  O-linked mucin-type glycoproteins in normal and malignant colon mucosa: lack of T-antigen expression and accumulation of Tn and sialosyl-Tn antigens in carcinomas.

Authors:  T F Orntoft; N Harving; N C Langkilde
Journal:  Int J Cancer       Date:  1990-04-15       Impact factor: 7.396

8.  Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA).

Authors:  P Y Fung; B M Longenecker
Journal:  Cancer Res       Date:  1991-02-15       Impact factor: 12.701

9.  Antibody to epiglycanin and radioimmunoassay to detect epiglycanin-related glycoproteins in body fluids of cancer patients.

Authors:  J F Codington; V P Bhavanandan; K J Bloch; N Nikrui; J V Ellard; P S Wang; R W Jeanloz
Journal:  J Natl Cancer Inst       Date:  1984-11       Impact factor: 13.506

10.  Ultrastructural and histochemical differences in cell surface properties of strain-specific and nonstrain-specific TA3 adenocarcinoma cells.

Authors:  S C Miller; E D Hay; J F Codington
Journal:  J Cell Biol       Date:  1977-03       Impact factor: 10.539

View more
  18 in total

Review 1.  Immunotherapeutic approaches for the treatment of breast cancer.

Authors:  K L Knutson; K Schiffman; K Rinn; M L Disis
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

2.  Selection of peptide ligands for the antimucin core antibody C595 using phage display technology: definition of candidate epitopes for a cancer vaccine.

Authors:  P Laing; P Tighe; E Kwiatkowski; J Milligan; M Price; H Sewell
Journal:  Clin Mol Pathol       Date:  1995-06

Review 3.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

Review 4.  Lung cancer immunotherapy.

Authors:  Luis E Raez; Steven Fein; Eckhard R Podack
Journal:  Clin Med Res       Date:  2005-11

5.  Tumor-associated antigens in breast cancer.

Authors:  Carmen Criscitiello
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

6.  Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.

Authors:  V Apostolopoulos; G A Pietersz; B E Loveland; M S Sandrin; I F McKenzie
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

Review 7.  Tecemotide: an antigen-specific cancer immunotherapy.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael Wolf; Michael W DeGregorio
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 8.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

9.  Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant.

Authors:  G D MacLean; M Reddish; R R Koganty; T Wong; S Gandhi; M Smolenski; J Samuel; J M Nabholtz; B M Longenecker
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

10.  Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases.

Authors:  Mika Kamata; Kaori Denda-Nagai; Nobuyoshi Kubota; Satoshi Aida; Kazuyoshi Takeda; Tatsuro Irimura
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.